C000020289 Fees and Costs — Allspring Target 2030 Fund, Class C
Data updated: 2022-07-29
The net expense ratio is 1.35% (1.45% before fee waivers). This share class carries a deferred sales charge of up to 1.00%. Portfolio turnover was 96%.
C000020289 Fees and Expenses
Annual operating expenses and sales charges of C000020289. Prospectus, as of June 30, 2022.
| Annual operating expenses | |
|---|---|
| Management fee | 0.10% |
| 12b-1 fee | 0.75% |
| Other expenses | 0.49% |
| Gross expense ratio | 1.45% |
| Fee waiver | −0.10% |
| Net expense ratio | 1.35% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 1.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
C000020289 Costs Over Time
On $10,000 invested in C000020289, assuming 5% a year before costs, total costs come to $839 over 5 years, cutting the return by 1.42% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Sales charges | $104 | $0 | $0 |
| Fund expenses (net expense ratio 1.35%) | $142 | $441 | $761 |
| Lost growth on money paid in costs | $0 | $22 | $77 |
| Total costs | $245 | $463 | $839 |
| Value after costs | $10,255 | $11,114 | $11,924 |
| Impact on return, per year | 2.45% | 1.42% | 1.42% |
C000020289 Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending February 28, 2022.
- Explicit cost rate (commissions ÷ average net assets): —
- Total broker commissions: —
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 96%
- Securities lending: none during the year
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.